Ovid Therapeutics Inc. OVID
We take great care to ensure that the data presented and summarized in this overview for Ovid Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OVID
View all-
Rubric Capital Management LP New York, NY5.32MShares$5.69 Million0.12% of portfolio
-
Madison Avenue Partners, LP New York, NY4.08MShares$4.37 Million0.53% of portfolio
-
Black Rock Inc. New York, NY3.99MShares$4.27 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA3.85MShares$4.12 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.09MShares$3.31 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N42.5MShares$2.68 Million0.12% of portfolio
-
Acadian Asset Management LLC Boston, MA1.66MShares$1.78 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.49MShares$1.59 Million0.03% of portfolio
-
Jpmorgan Chase & CO New York, NY1.47MShares$1.57 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL1.4MShares$1.5 Million0.01% of portfolio
Latest Institutional Activity in OVID
Top Purchases
Top Sells
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Insider Transactions at OVID
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2024
|
Jeremy M Levin CEO |
BUY
Open market or private purchase
|
Direct |
18,248
+0.5%
|
$36,496
$2.76 P/Share
|
|
Feb 22
2024
|
Jason Tardio Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,125
+50.0%
|
-
|
|
Feb 22
2024
|
Thomas Michael Perone General Counsel, Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
28,125
+50.0%
|
-
|
|
Feb 22
2024
|
Jeffrey A Rona CBFO |
BUY
Grant, award, or other acquisition
|
Direct |
28,125
+50.0%
|
-
|
|
Dec 04
2023
|
Jeremy M Levin CEO |
SELL
Bona fide gift
|
Direct |
1,146,550
-12.91%
|
-
|
|
Sep 12
2022
|
Jason Tardio Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
17,344
-100.0%
|
$34,688
$2.15 P/Share
|
|
Jul 01
2022
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
5,750,000
+50.0%
|
-
|
|
Jul 01
2022
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
5,750,000
-100.0%
|
-
|
|
Jul 14
2021
|
Amit Rakhit President and CMO |
SELL
Open market or private sale
|
Direct |
34,017
-4.47%
|
$102,051
$3.71 P/Share
|
|
Jul 14
2021
|
Amit Rakhit President and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,017
+4.28%
|
$34,017
$1.89 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 84.4K shares |
|---|---|
| Open market or private purchase | 18.2K shares |
| Bona fide gift | 1.15M shares |
|---|